What has Vertex Pharmaceuticals managed to do in the five years of operation in our country?
We are a biotechnology company with global operations. We invest in scientific innovation to discover medicines and make them available to critically ill patients. This is an important moment for us. After five years of our operations, cystic fibrosis patients now have real access to drugs that have been developed in our laboratories. Now, patients can be included in therapy and be helped. Moreover, as far as our achievements are concerned, we have created a team that operates in the Polish and Czech markets. We operate mainly in Warszawa. We are a close-knit and strong team, of which I am extremely proud.
Czytaj więcej
Misją naszej firmy jest pomoc pacjentom chorym na mukowiscydozę i inne ciężkie choroby – mówił Marek Macyszyn, dyrektor generalny na Polskę i Czechy Vertex Pharmaceuticals.
Is the treatment of cystic fibrosis of greatest importance to your company?
Yes. Our goals are to invest in innovation and drug discovery. Cystic fibrosis is the first therapeutic area where the company has grown very strongly. Over the company’s thirty-odd years of global existence, more than 20 years have been in research and development. After years of exploration and discovery, we have made available drugs that directly affect the cause of cystic fibrosis. These drugs are also available for Polish patients. Cystic fibrosis and investing in innovation are a priority.
How many people suffer from the disease?
Cystic fibrosis is a very severe and rare disease with approximately 1,800 patients in Poland. It is a multisystem genetic disease that places a heavy burden on patients and their families, carers, and partners.
